Potential mechanisms underlying CDK5 related Osteosarcoma progression

被引:8
作者
Bao, Hang-xing [1 ,2 ]
Bi, Qing [3 ,6 ]
Han, Yong [4 ,6 ]
Zhao, Chen [3 ,6 ]
Zou, Hai [5 ,6 ]
机构
[1] Zhejiang Chinese Med Univ, Clin Med Coll 1, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Hosp Tradit Chinese Med, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Prov Peoples Hosp, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Prov Peoples Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China
[5] Zhejiang Prov Peoples Hosp, Dept Cardiol, Hangzhou, Zhejiang, Peoples R China
[6] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China
关键词
Osteosarcoma; cyclin-dependent kinase 5; tumor immune escape; therapeutic targets; EPITHELIAL-MESENCHYMAL TRANSITION; ZIPPER KINASE MELK; CELL LUNG-CANCER; BREAST-CANCER; STEM-CELLS; EXPRESSION; IMMUNOTHERAPY; CARCINOMA; CYCLE; ACTIVATION;
D O I
10.1080/14728222.2017.1310194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Identification of new prognostic biomarkers and therapeutic targets is of crucial importance for patients with osteosarcoma. Cyclin-dependent kinase 5 (CDK5) is overexpressed in several tumor types. However, the exact role CDK5 plays in osteosarcoma is still unknown.Methods: In this study, we explored the association between CDK5 expression and the prognosis of osteosarcoma patients using publicly available gene expression datasets. Potential molecular mechanisms underlying its pro-malignant role in cancer progression were also discussed.Results: We demonstrated that tricarboxylic acid (TCA) cycle is activated while antigen presentation is repressed in patients with CDK5 overexpression and poor survival. This results indicated that sufficient energy production and tumor immune escape are important characteristics and potential therapeutic targets for this subgroup of osteosarcoma patients. Furthermore, several critical hub genes that are associated with CDK5 related osteosarcoma progression such as MELK were identified.Conclusion: This study discussed the pro-malignant role of CDK5 and potential mechanisms involved. Further preclinical and clinical studies to develop CDK5 based treatments are warranted.
引用
收藏
页码:455 / 460
页数:6
相关论文
共 36 条
[1]   Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma [J].
Ahmed, Nabil ;
Brawley, Vita S. ;
Hegde, Meenakshi ;
Robertson, Catherine ;
Ghazi, Alexia ;
Gerken, Claudia ;
Liu, Enli ;
Dakhova, Olga ;
Ashoori, Aidin ;
Corder, Amanda ;
Gray, Tara ;
Wu, Meng-Fen ;
Liu, Hao ;
Hicks, John ;
Rainusso, Nino ;
Dotti, Gianpietro ;
Mei, Zhuyong ;
Grilley, Bambi ;
Gee, Adrian ;
Rooney, Cliona M. ;
Brenner, Malcolm K. ;
Heslop, Helen E. ;
Wels, Winfried S. ;
Wang, Lisa L. ;
Anderson, Peter ;
Gottschalk, Stephen .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) :1688-+
[2]   Feeding the TCA cycle in vivo [J].
Alderton, Gemma K. .
NATURE REVIEWS CANCER, 2016, 16 (04) :198-198
[3]   From Krebs to clinic: glutamine metabolism to cancer therapy [J].
Altman, Brian J. ;
Stine, Zachary E. ;
Dang, Chi V. .
NATURE REVIEWS CANCER, 2016, 16 (10) :619-634
[4]   NCBI GEO: archive for functional genomics data sets-update [J].
Barrett, Tanya ;
Wilhite, Stephen E. ;
Ledoux, Pierre ;
Evangelista, Carlos ;
Kim, Irene F. ;
Tomashevsky, Maxim ;
Marshall, Kimberly A. ;
Phillippy, Katherine H. ;
Sherman, Patti M. ;
Holko, Michelle ;
Yefanov, Andrey ;
Lee, Hyeseung ;
Zhang, Naigong ;
Robertson, Cynthia L. ;
Serova, Nadezhda ;
Davis, Sean ;
Soboleva, Alexandra .
NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) :D991-D995
[5]   GATHER: a systems approach to interpreting genomic signatures [J].
Chang, Jeffrey T. ;
Nevins, Joseph R. .
BIOINFORMATICS, 2006, 22 (23) :2926-2933
[6]   Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients [J].
Chiker, Sara ;
Pennaneach, Vincent ;
Loew, Damarys ;
Dingli, Florent ;
Biard, Denis ;
Cordelieres, Fabrice P. ;
Gemble, Simon ;
Vacher, Sophie ;
Bieche, Ivan ;
Hall, Janet ;
Fernet, Marie .
CELL CYCLE, 2015, 14 (19) :3066-3078
[7]   Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor [J].
Chung, Suyoun ;
Kijima, Kyoko ;
Kudo, Aiko ;
Fujisawa, Yoshiko ;
Harada, Yosuke ;
Taira, Akiko ;
Takamatsu, Naofumi ;
Miyamoto, Takashi ;
Matsuo, Yo ;
Nakamura, Yusuke .
ONCOTARGET, 2016, 7 (14) :18171-18182
[8]   Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer [J].
Davidson, Shawn M. ;
Papagiannakopoulos, Thales ;
Olenchock, Benjamin A. ;
Heyman, Julia E. ;
Keibler, Mark A. ;
Luengo, Alba ;
Bauer, Matthew R. ;
Jha, Abhishek K. ;
O'Brien, James P. ;
Pierce, Kerry A. ;
Gui, Dan Y. ;
Sullivan, Lucas B. ;
Wasylenko, Thomas M. ;
Subbaraj, Lakshmipriya ;
Chin, Christopher R. ;
Stephanopolous, Gregory ;
Mott, Bryan T. ;
Jacks, Tyler ;
Clish, Clary B. ;
Heiden, Matthew G. Vander .
CELL METABOLISM, 2016, 23 (03) :517-528
[9]   Regulatory networks defining EMT during cancer initiation and progression [J].
De Craene, Bram ;
Berx, Geert .
NATURE REVIEWS CANCER, 2013, 13 (02) :97-110
[10]   Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer [J].
Deng, Junli ;
Wang, Li ;
Chen, Hongmin ;
Hao, Jingli ;
Ni, Jie ;
Chang, Lei ;
Duan, Wei ;
Graham, Peter ;
Li, Yong .
ONCOTARGET, 2016, 7 (34) :55771-55788